학술논문

Neoadjuvant chemoradiotherapy for rectal cancer: how important is tumour regression?
Document Type
Article
Source
ANZ Journal of Surgery. Dec2017, Vol. 87 Issue 12, pE233-E239. 7p. 3 Charts, 1 Graph.
Subject
*CHEMORADIOTHERAPY
*RECTAL cancer treatment
*CANCER relapse
*TUMOR treatment
*HEALTH outcome assessment
*PREVENTION
Language
ISSN
1445-1433
Abstract
Background Pathological complete response following neoadjuvant chemoradiotherapy ( CRT) for locally advanced rectal cancer is associated with reduced local recurrence and improved long-term outcome. However, the prognostic value of a partial response, or of tumour regression in patients with metastatic disease, is less clear. Methods We present a single-centre cohort study of 205 patients with stage II-IV rectal cancer treated with surgery and neoadjuvant CRT between 2006 and 2013. Tumour regression was assessed using the Dworak system. Results The probability of 3-year recurrence-free survival ( RFS) was 95% for Dworak grade 4, 82% for grade 3, 64% for grade 2 and 53% for grade 1 ( P = 0.0005). In univariate regression analysis, Dworak grade was associated with RFS (hazard ratio (HR) 0.51, P < 0.0001; trend analysis) and cancer-specific survival ( HR 0.52, P = 0.002). In multivariate analysis, Dworak grade remained an independent predictor of RFS ( HR 0.62, P = 0.012), along with clinical metastases stage, resection margin status, the presence or absence of extramural venous invasion and type of surgical procedure. Conclusions Tumour regression grade after neoadjuvant CRT was an independent prognostic factor for RFS, highlighting the importance of the degree of local response to CRT. [ABSTRACT FROM AUTHOR]